West Pharmaceutical Services, Inc.
WST Healthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024. In the quarter to June 2026, revenue grew 13.8%, EPS grew 19.2%, free cash flow fell 20.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow WST
West Pharmaceutical Services, Inc. (WST) Return on equity
West Pharmaceutical Services, Inc.'s return on equity over the twelve months to 30 June 2026 was 19.1%, up 2.2 percentage points from fiscal 2025 (16.9%). Over the past ten years it has ranged from 9.65% (fiscal 2015) to 31.6% (fiscal 2021); the current reading is higher than 55% of that period. That is above the Medical Instruments & Supplies industry median of −1.32% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 16.9% | (0.86) |
| FY2024 | 17.7% | (3.61) |
| FY2023 | 21.3% | (2.02) |
| FY2022 | 23.3% | (8.25) |
| FY2021 | 31.6% | 11.39 |
| FY2020 | 20.2% | 3.92 |
| FY2019 | 16.3% | 0.82 |
| FY2018 | 15.5% | 2.89 |
| FY2017 | 12.6% | (0.84) |
| FY2016 | 13.4% | 3.76 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| SOLV Solventum Corporation compare | 34.0% |
| RMD ResMed Inc. compare | 24.3% |
| WST West Pharmaceutical Services, Inc. | 19.1% |
| COO The Cooper Companies, Inc. compare | 6.84% |
| BDX Becton, Dickinson and Company compare | 3.77% |
| ALC Alcon compare | 2.94% |
| RGEN Repligen Corporation compare | 1.99% |
| MDLN Medline Inc. compare | 0.00% |
| BAX Baxter International Inc. compare | −15.8% |
| Medical Instruments & Supplies industry median | −1.32% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on WST
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement